 |
Prospector
Profile
111-06
|
| |
| Dyadic International, Inc. |
NAICS |
541710 |
| 140 Intracoastal Pointe Drive, Suite 404
Jupiter, FL 33477 |
Description |
Biotechnology |
| (561) 743-8333 |
Employees |
125 |
| http://www.dyadic.com/wt/home |
Revenue |
(mil) |
15.3830 |
| |
Income |
(mil) |
-10.8820 |
| |
Assets |
(mil) |
45.1370 |
| |
Liability |
(mil) |
16.9480 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Default
|
| |
|
Event:
Dyadic International, Inc.'s wholly-owned subsidiary, Dyadic International (USA), Inc., on Jan. 2, 2008, received a purported declaration of default from the Mark A. Emalfarb Trust under agreement dated October 1, 1987 relating to Dyadic (USA)'s Revolving Note in favor of the Emalfarb Trust dated as of May 29, 2003 with a maturity date of January 1, 2009. Principal under the Note bears interest at the rate of 8% per annum, 14% following a default under the Note; the Note has a principal balance of approximately $2.4 million and is secured by certain of Dyadic (USA)'s assets.
|
| |
|
Intellectual Property:
In October 2006, the Company was granted U.S. patent 7,122,330, “High-Throughput Screening of Expressed DNA Libraries in Filamentous Fungi,” by the U.S. Patent and Trademark Office. This patent grant will expand the patent protection for the C1 HTS Technology and broad claims covering a number of other industrially relevant fungi for applications in cellulosic ethanol and other key markets. The Company owns 4 issued U.S. patents, 28 issued and 2 allowed International patents and 52 U.S. and International filed and pending patent applications which provide broad protection for the Dyadic Platform Technology and their products and commercial applications. [SEC Filing 10-KSB 04-02-07]
|
| |
|
Description:
Dyadic International is a biotechnology company that uses its patented and proprietary technologies to conduct research and development activities for the discovery, development, and manufacture of products and enabling solutions to the bioenergy, industrial enzyme and pharmaceutical industries.
|
| |
|
Officers:
Mark A. Emalfarb (Chair, Pres. & CEO); Glenn E. Nedwin (EVP, Chief Scientific Officer & Dir.); Wayne Moor (VP & CFO); Kent M. Sproat (EVP); Ratnesh Chandra (SVP); Daniel Michalopoulos (VP); Charles W. Kling IV (VP); Alexander Bondar (VP); Richard J. Berman (Dir.); Robert B. Shapiro (Dir.); Stephen J. Warner (Dir.); Harry Z. Rosengart (Dir.)
|
| |
|
Auditor:
Ernst &Young LLP
|
| |
|
Securities:
Common Stock-Symbol DIL; AMEX;
29,939,375 common shares outstanding as of March 28, 2007.
|
| |
| |
| |
| return to main page |
|
|
